In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
T cells and enhances immunotherapy-induced tumor regression in mice. These investigations yield insight into aPD-1 target engagement in vivo and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.